New drug may help kids with sickle cell disease get life-changing transplants despite antibody barriers

NCT ID NCT06358638

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a drug called daratumumab before a stem cell transplant can prevent a serious complication called pure red blood cell aplasia in children with sickle cell disease. The transplant uses a gentle, low-intensity approach and a matched sibling donor. About 12 children and teens aged 2 to 24 who have antibodies against their donor's red blood cells will take part. The goal is to see if this approach improves survival and reduces complications one year after transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's National Hospital

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact